Indicate: Evaluate the potential benefits of a new heart failure diagnostic system for heart failure patients with implanted cardiac resynchronization therapy devices, and establish the feasibility of implementing it into clinical practice.
Astronaut: The purpose of this study is to investigate whether aliskiren in addition to standard care is safe and has beneficial effects by delaying the time of first occurrence of either cardiovascular death or heart failure re-hospitalization within 6 months, in patients experiencing
acute decompensated heart failure.
BAY 63-2521: This study will be a dose finding study to evaluate the hemodynamic effects of Riociguat as well as safety and kinetics in subjects with pulmonary hypertension associated with left ventricular systolic dysfunction. The study drug is given over 16 weeks to evaluate the effects of Riociguat versus placebo on top of optimized CHF medication.